Olaparib Application Scope

• Maintenance treatment of adult patients with BRCA-mutated ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
• Treatment of HER2-negative, BRCA-mutated metastatic breast cancer
• BRCA-mutated metastatic pancreatic cancer
• BRCA-mutated, castration-resistant prostate cancer

Olaparib Characteristics

Ingredients: Olaparib
Properties: Film-coated tablets, off-white to yellowish-white, oval-shaped
Packaging Specification: 100 mg or 150 mg per tablet, available in bottles of 60 tablets
Storage: Store at room temperature below 30°C. Keep in the original container to protect from moisture.
Expiry Date: Refer to outer packaging (typically 24 months from manufacture)
Executive Standard: In compliance with FDA and EMA regulatory standards
Approval Number: Example (U.S.): NDA 208558 (150 mg tablet)
Date of Revision: August 2025 (fill with most recent date if available)
Manufacturer: AstraZeneca UK Limited

Guidelines for the Use of Lynparza

Dosage and Administration:
- Recommended Dose: 300 mg (two 150 mg tablets) orally twice daily
- Administration: Oral route; consistent timing each day is advised
- Missed Dose: If a dose is missed, take the next dose at the usual scheduled time. Do not take extra tablets to make up for a missed dose.
Adverse Reactions:
- Common Adverse Reactions (≥5% and >3% higher than placebo):
  • Nausea
  • Fatigue (including asthenia)
  • Anemia
  • Vomiting
  • Diarrhea
  • Decreased appetite
- Serious Adverse Reactions:
  • Myelodysplastic syndrome/Acute myeloid leukemia (MDS/AML)
  • Pneumonitis
  • Severe anemia and other hematologic toxicities
Contraindications:Patients with known hypersensitivity to olaparib or any component of the formulation
Precautions:
- - Myelosuppression:
    Monitor blood counts monthly during treatment
  - MDS/AML Risk:
    Discontinue treatment if confirmed
  - Pulmonary Toxicity:
    Monitor for new or worsening respiratory symptoms
  - Pregnancy and Lactation:
    Avoid use during pregnancy; advise effective contraception. Discontinue breastfeeding during treatment and for 1 month after last dose

Olaparib Interactions

CYP3A Inhibitors/Inducers:
• Avoid strong or moderate CYP3A inhibitors (e.g., ketoconazole)
• Avoid CYP3A inducers (e.g., rifampin, carbamazepine)
• Adjust dose if coadministration unavoidable
Other considerations:
• Use caution with drugs causing myelosuppression

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.